Cellics Therapeutics leverages the multifaceted Cellular Nanoparticle (CNP) technology to develop nano-therapeutics and drive breakthrough drug delivery for mRNA, siRNA, proteins and small molecules. Cellics’ two dynamic nanoplatforms, Cellular Nanosponges and the Cellular Nanoparticle drug delivery technology, harness the power of cell membranes to craft specialized nanoparticle-based therapeutics. Derived from a variety of wild-type or engineered human cells, the CNP technology has the potential to address a broad range of diseases. Cellics is a privately held San Diego-based biopharmaceutical company founded by UC San Diego Professor Liangfang Zhang.
Advancing Transformative Therapies for Serious Diseases
Harnessing the power of cell membranes in specialized nanoparticle-based therapeutics.
Our team includes life sciences industry veterans with deep expertise across a number of disciplines who are committed to developing novel therapeutics.
Cellics Core Principles
We are committed to upholding the core principles we have set for ourselves in order to maintain our integrity and achieve our goals.
We are honest with ourselves and transparent with our actions.
We are tireless in applying scientific excellence to seek new solutions for big problems.
We are inspired to take action, to be courageous, to break boundaries, for the well-being of patients.
We thrive together by recognizing and respecting each other’s strengths and weaknesses.
Cellics seeks to collaborate with industry leaders to advance the development of the CNP technology to provide potentially better patient outcomes.
Professor Liangfang Zhang’s group at the University of California San Diego (UCSD) invented the CNP platform technology, from which Cellics aims to advance therapeutics and innovative drug delivery solutions. Cellics and UCSD have a close collaboration to further develop core platform technologies.
Cellics and CARB-X have a strategic partnership of up to $15 Million to develop a novel macrophage nanosponge for treating sepsis. CARB-X will be supporting Cellics through preclinical and Phase 1 studies to further clinical development and obtain regulatory approval.
A Revolutionary Approach to Treatment and Drug Delivery
Cellics’ dynamic nanoplatforms leverage the power of cell membranes to craft specialized nanoparticles. Derived from a variety of wild type or engineered human cells, the cellular nanoparticle technology has the potential to improve therapeutic effectiveness and overcome drug delivery challenges.